Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06958107 · ClinicalTrials.gov registry record
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
A clinical trial of Sarcoma, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 300
- Enrollment target
- 2
- Study locations
NCT06958107: Recruiting study of Sarcoma, sponsored by Wake Forest University Health Sciences.
NCT06958107 is a study of Sarcoma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 300 participants, below the 919-participant average among 122 other Sarcoma trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06958107, a study of Sarcoma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).
Primary Outcome
A binary variable indicating whether or not ctDNA was detected by low pass whole genome sequencing (LP-WGS) in the sample.
Conditions Studied
Interventions
- OTHER Non-Metastatic and Resectable
- OTHER Metastatic and Un-resectable
- OTHER No evidence of disease, under surveillance
- OTHER ALT or WDLS
Study Locations (2)
North Carolina
- Levine Cancer Institute - Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2030-01 |
What NCT06958107 shows while recruiting
NCT06958107 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 919-participant average among 122 other Sarcoma trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Non-Metastatic and Resectable is the first listed.
NCT06958107 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06958107 about?
NCT06958107 is a clinical study titled "LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients". The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).
What is the current status of trial NCT06958107?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-08-21. Estimated completion is 2030-01.
What conditions does trial NCT06958107 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT06958107?
The interventions under investigation include: Non-Metastatic and Resectable (OTHER), Metastatic and Un-resectable (OTHER), No evidence of disease, under surveillance (OTHER), ALT or WDLS (OTHER).
Who is sponsoring clinical trial NCT06958107?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06958107 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06958107's enrollment target sits among peer trials
300 19th of 122 higher than 104 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy